Low-molecular-weight heparins should be used with caution in patients with chronic kidney disease

2008 ◽  
Vol 4 (9) ◽  
pp. 488-489 ◽  
Author(s):  
Maurizio Gallieni ◽  
Mario Cozzolino ◽  
Chiara Ronga ◽  
Diego Brancaccio
Keyword(s):  
Chronic Kidney Disease ◽  
Molecular Weight ◽  
Kidney Disease ◽  
Low Molecular Weight ◽  
Low Molecular Weight Heparins

Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease

2004 ◽  
Vol 43 (3) ◽  
pp. 531-537 ◽  
Author(s):  
Vasim Farooq ◽  
Janet Hegarty ◽  
Thangavelu Chandrasekar ◽  
Elizabeth H. Lamerton ◽  
Sandip Mitra ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Molecular Weight ◽  
Kidney Disease ◽  
Low Molecular Weight ◽  
Low Molecular Weight Heparins

Electrophoretic patterns of proteinuria in feline spontaneous chronic kidney disease

2019 ◽  
Vol 22 (2) ◽  
pp. 114-121
Author(s):  
Marco Giraldi ◽  
Saverio Paltrinieri ◽  
Paola Scarpa
Keyword(s):  
Chronic Kidney Disease ◽  
At Risk ◽  
Molecular Weight ◽  
Kidney Disease ◽  
Sodium Dodecyl ◽  
Electrophoretic Pattern ◽  
Low Molecular Weight ◽  
Tubular Proteinuria ◽  
Exact Test ◽  
Electrophoretic Patterns

Objectives The purpose of this study was to describe the electrophoretic patterns of proteinuria in cats at risk of and cats with chronic kidney disease (CKD), and to investigate whether the presence of high-molecular-weight (HMW) and low-molecular-weight (LMW) proteins were associated with CKD, proteinuria and/or disease progression. Methods Healthy cats at risk of developing renal disease (n = 17) and cats affected with CKD at different stages (n = 22) were prospectively enrolled and sampled over time. Seventy urine samples were included and assayed with a commercially available sodium dodecyl sulfate–agarose gel electrophoresis (SDS-AGE) method. Each sample (gel lane) was inspected to identify albumin, HMW and LMW proteins, and an electrophoretic pattern (albuminuria, glomerular, tubular, mixed or negative) was assigned accordingly. Fisher’s exact test was used to assess the distribution of HMW and LMW proteins in cats grouped according to International Renal Interest Society stage and to the magnitude of proteinuria, and to assess if HMW and LMW proteins at the time of inclusion were associated with the development and progression of CKD. Results In samples of cats at risk, the most common pattern was glomerular (84.6%); glomerular pattern was also common in cats with CKD (54.2%), although mixed proteinuria and tubular proteinuria were also present (29.5% and 11.4%, respectively). The presence of LMW proteins was associated with CKD ( P <0.0001) and to a urine protein:creatinine ratio >0.2 ( P = 0.025). Both HMW and LMW proteins were not associated with progression of CKD within 6 months (n = 14). Conclusions and relevance Our results showed that HMW proteinuria is common in healthy cats at risk of developing CKD, although the pathological significance needs to be confirmed. The detection of LMW proteins in urine of cats suspected to be affected by CKD, especially in non-azotaemic, non-proteinuric or borderline proteinuric cats, suggests the presence of kidney damage.

Dosing Low Molecular Weight Heparins in Kidney Disease

2010 ◽  
Vol 23 (3) ◽  
pp. 205-209 ◽  
Author(s):  
Manny Saltiel
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Consensus Statement ◽  
Low Molecular Weight ◽  
Low Molecular Weight Heparins ◽  
Risk Of Bleeding ◽  
Increased Risk ◽  
Severe Chronic Kidney Disease ◽  
Dosing Strategies ◽  
The Individual

The low molecular weigh heparins (LMWHs) are primarily eliminated renally, and current literature indicates that there is a reduction in clearance and an increase in half-life of LMWHs in patients with severe chronic kidney disease (CKD) associated with elevated anti-Xa levels and an increased risk of bleeding. It therefore becomes clinically prudent to evaluate dosing adjustments in CKD. The American College of Chest Physicians (ACCP), in its 2008 consensus statement, recommends 5 possible approaches to dosing LMWH in patients with severe CKD. In evaluating the individual compounds, enoxaparin, dalteparin, and tinzaparin, this article attempts to address the preferred dosing strategies.

Sign in / Sign up

Export Citation Format

Share Document